News for Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”œCorbus” or the ”œCompany”), today announced that Yuva

**media[549724]**

On December 31, 2024, Orbimed Advisors LLC executed a significant transaction involving Corbus Pharmaceuticals Holdings Inc (CRBP). The firm reduced its holding

**media[540758]**

**media[537519]**

**media[526211]**

NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”œCorbus” or the ”œCompany”), today announced that Yuva

**media[486994]**

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment NORWOOD, Mass., Dec. 09, 2024 (GLO

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Corbus Pharmaceuticals Holdings...

The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.

**media[481899]**

Investing in healthcare stocks during lean economic times is generally regarded as defensive.

Overview of Recent Transaction On October 4, 2024, Cormorant Asset Management, LP (Trades, Portfolio) made a significant new investment in the biotechnology sec

Recent Transaction Overview On September 30, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a significant adjustment to its investment in Avalo Therapeutic

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 0.5% on Friday. The Dow traded up 0.01% to 42,029.86 while ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 0.2% on Friday. The Dow traded up 0.09% to 42,064.34 while the NAS...

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the...

Corbus Pharmaceuticals Holdings has seen an 800% stock price increase in 2024. See why CRBP is one of the best performing equities in the market right now.